Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to access the efficacy and safety of LCZ696 compared to
olmesartan in elderly Asian patients for the treatment of hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Olmesartan Olmesartan Medoxomil Sacubitril and valsartan sodium hydrate drug combination